Services & Sectors

The global landscape for pharmaceutical and biotechnology companies continues to undergo dynamic change. These changes include price pressure, outcomes-based reimbursement, and more restrictive policy that challenge sales and R&D productivity, as well as new technologies, treatment pathways, and personalized medicine advancements that unlock avenues for growth.
Harrison Hayes supports large, mid-size, and small pharma and biotech companies with expert-driven insights to navigate the intersection of scientific, clinical, and business strategy.

Within the medical device landscape, miniaturization, robotics, imaging advancements, remote monitoring, and software-enabled smart devices are shifting sites of care and creating new business models. At the same time, provider consolidation, value-based purchasing and increasing patient empowerment are forcing MedTech companies to rethink traditional commercial models.
Harrison Hayes helps medical device companies successfully think beyond traditional approaches and maximize opportunity in new ventures, whether that is portfolio growth through acquisition or product planning in new markets.
Harrison Hayes works with the world’s leading medical device companies on their most important growth initiatives. From product development through launch, we support clients in making critical decisions to drive novel innovation, grow share, and compete to win in rapidly developing spaces. Harrison Hayes supports executives across numerous functions—including marketing and sales, corporate strategy and business development, and R&D and clinical—to lead growth initiatives in highly specialized device categories.

Next -generation sequencing, personalized medicine, and point of care technology, among other trends—have created new opportunities for forward-thinking diagnostics companies.
As tools and technologies emerge to improve research efficiency and enable more targeted therapies, companies face new challenges in establishing differentiated go-to-market strategies, adapting to evolving reimbursement dynamics, and staying ahead of shifting customer needs.
Harrison Hayes supports companies across a broad range of diagnostics and research tools to achieve and sustain growth.
Harrison Hayes focuses on creating tailored strategies to support companies in the diagnostics and research tools space.

In an era of value-based care, rapid health technology innovation, and changing regulatory landscape, Harrison Hayes consultants help develop winning business strategies for the world’s leading software providers and digital health IT (HIT) companies.
We work with clients spanning the IT advancement spectrum, from dedicated HIT vendors seeking a cutting edge over their rivals, to traditional device and pharma companies tasked with creating a digital health strategy.
From development through launch, Harrison Hayes supports clients in making critical decisions to maintain market positioning, win new customers, maintain share, and compete to win in a rapidly developing space.
For health IT clients, we offer a breadth of services ranging from mergers and acquisitions (M&A) advisory (landscape assessments, target identification, commercial due diligence) to product planning and roadmap development. We work to tackle white space growth opportunities, set best-in-class commercial positioning, and develop new product concepts.
Harrison Hayes has helped clients adapt to new value-based care (VBC) initiatives from government agencies, navigate the increasingly consolidated provider landscape, and enter new markets.